HFPN Strategic Adviser Ed Harding discusses cardiovascular care with Health Europa Quarterly

News & Events

19 January 2022

Ed Harding, Strategic Adviser to the Heart Failure Policy Network (HFPN), recently spoke with Health Europa Quarterly (HEQ) about the key challenges affecting the diagnosis, screening and treatment of heart failure.

In the interview, which is included in issue 20 of the HEQ online publication, Ed outlined how the HFPN was founded and its role in addressing gaps in heart failure care. The conversation also turned to learnings from the inaugural Heart Failure Policy Summit in 2021, which looked at heart failure in light of health inequalities, health system sustainability and the impact of COVID-19.

The key takeaway from the discussion is the need to increase knowledge and awareness of cardiovascular disease, and to make rapid improvements in European heart failure policy. ‘If you look at studies across Europe, we know that we are not very good at helping people who live with established cardiovascular disease,’ says Ed. ‘The message I would convey to anyone reading this article is that their government, or their region, should at least have a position, even if it’s not a strategy, on heart failure.’

Read the full article: https://www.healtheuropa.eu/connecting-care-for-cardiovascular-diseases/112819/


More from News & Events

New briefing provides heart failure advocates with actionabl
New briefing provides heart failure advocates with actionabl...
15 May 2023
The final advocacy briefing in our From guidelines to action series highlights the opportunities for heart failure advocates to improve care in Germany. ...
Read article
Tackling the overlooked epidemic of heart failure in Germany
Tackling the overlooked epidemic of heart failure in Germany...
04 May 2023
Heart failure is prevalent in Germany, but is under-recognised. Key stakeholders came together at the German Heart Failure Roundtable to discuss the need for policy change and comp...
Read article
The Heart Failure Policy Network is an independent, multidisciplinary platform made possible with financial support from AstraZeneca, CSL Vifor, Boehringer Ingelheim and Roche Diagnostics. The content produced by the Network is not biased toward any specific treatment or therapy. All outputs are guided and endorsed by the Network’s members. All members provide their time for free. The Network is hosted by The Health Policy Partnership .